Email ID
Password
AstraZeneca is facing more disappointment with the development of its new anticancers after its experimental anti-angiogenic drug Recentin (cediranib) did not ...
GlaxoSmithKline, which has yet to decide on whether or not to participate in UNITAID 's AIDS medicines patent pool, sees more value in its own licensing ...
Ark Therapeutics has withdrawn the EU filing of its brain cancer gene therapy candidate Cerepro (sitimagene ceradenovec), dropping a previous appeal over a ...
Genmab's experimental EGFR-targeted monoclonal antibody zalutumumab (HuMax-EGFr), one of its most advanced products in development, has failed to meet its ...
 
Lexicon Pharmaceuticals has announced plans to offer for sale $95 million of its common stock in an underwritten public offering. It could also sell up to $14.25 million worth of shares as an ...
Sanofi-Aventis has exercised its option to combine its animal health business Merial with Intervet/Schering-Plough Animal Health , Merck & Co 's animal health unit. Sanofi-Aventis bought out Merck's ...
The UK firm Vernalis has regained full rights to the royalties on its only marketed product, the migraine treatment frovatriptan. It made a one-off net cash payment of $32.57 million to Paul Capital ...
Polpharma, one of Poland's largest pharmaceutical manufacturers, is buying an antibiotics production business from Bioton , another local company, for PLN 80 million ($8 million). Poland's office of ...
 
Thyroid cancer risks of anti-diabetic GLP-1 analogues are probably limited to rats and mice, suggests Novo Nordisk -sponsored research published this week in the journal Endocrinology. Investors, who ...
A post-hoc analysis of the failed DIAS-2 Phase III study of Lundbeck 's candidate for the treatment of ischaemic stroke, desmoteplase, suggests that the drug is effective in the sub-group of patients ...
Takeda and Lundbeck have unveiled details of new pivotal Phase III programmes for two novel molecules for major depressive disorder (MDD) being co-developed under their 2007 alliance for mood and ...
Synta Pharmaceuticals has received the go-ahead from the US FDA to resume development of its novel anticancer elesclomol, an oxidative stress inducer whose closely watched Phase III trial in ...
 
Slovakia’s association of research-based pharmaceutical companies (SAFS) has elected a new board. Dr Pavol Trnovec of GlaxoSmithKline, who was previously its vice-chairman, will lead SAFS as ...
The US FDA recognises emerging and pandemic threats – and it aims to boost the development of cell-based viral vaccines with the publication of a final guidance entitled Guidance for Industry: ...
The Philippines government has announced a second wave of price cuts in the medicines sector under the government-mediated access price (GMAP) programme. Most reductions will come into effect on ...
Brazil's chamber for foreign trade, CAMEX, has published a list of 100 products coming from the US that will be subject to higher import duties following a WTO dispute over cotton subsidies. The list ...
 
Board changes at Cytos Biotechnology Cytos Biotechnology (Switzerland) has elected its vice-chairman, Dr Thomas Hecht , to succeed Dr ...
New board appointment at Orexigen Orexigen Therapeutics, a US biopharmaceutical company focused on the treatment of obesity, has ...
New appointment at Catalyst Biosciences Catalyst Biosciences , a US company focused on the discovery and development of engineered ...

Following the latest round of pharma mergers and as a long-time participant in this ...

Market Insight: Big pharma hit by Greece's fiscal crisis
Today

Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of ...

 Market Insight - Fear gives way to prudence a...

How to run clinical trials in the Middle East - why the GCC?
04 March 2010

A grouping of Middle Eastern countries came together under the auspices of the Gulf Co-operation ...

How to run clinical trials in the Middle East - Jordan
04 March 2010

Jordan has a population of 6.35 million and its GDP per capita is $5,000, while its healthcare ...

Genzyme's gambit: A hedge against Carl Icahn
18 February 2010
Christopher Spillane
The fall in Genzyme 's share price made it an obvious target. The Massachusetts based biotech ...

Logos are said to be an important part of an organisation's branding. Really good logos contribute ...

Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big ...

CPhI Worldwide 2009
13 October 2009
Scrip's official preview of CPhI Worldwide, ICSE, P-MEC and BioPh 2009

Scrip's Stock Tracker: January 2010
10 February 2010
Ashley Yeo
Fears that a market correction was imminent pushed the equity markets down as January tapered out, ...

EVENTS
11 March 2010
Cambridge, UK
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36